XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.23.3

Goodwill and Intangible Assets | 9 Months Ended
--- | ---
Sep. 30, 2023
Goodwill and Intangible Assets |
Goodwill and Intangible Assets | Note 10. Goodwill and Intangible Assets ​ The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Weighted-Average | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ |
​ |  | Life (Years) |  | Original Cost |  | Amortization |  | Net Book Value |
​ | ​ | (in thousands) |
Definite-lived intangible assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
BAQSIMI® product rights(1) | ​ | 24 | ​ | $ | 591,338 | ​ | $ | 6,159 | ​ | $ | 585,179 | ​
IMS (UK) international product rights(2) | ​ | 10 | ​ | ​ | 8,462 | ​ | ​ | 8,462 | ​ | ​ | — | ​
Patents |  | 12 | ​ |  | 486 | ​ | ​ | 372 | ​ |  | 114 | ​
Land-use rights |  | 39 | ​ |  | 2,540 | ​ | ​ | 799 | ​ |  | 1,741 | ​
Subtotal |  | 23 | ​ |  | 602,826 | ​ |  | 15,792 | ​ |  | 587,034 | ​
Indefinite-lived intangible assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Trademark |  | * | ​ |  | 29,225 | ​ |  | — | ​ |  | 29,225 | ​
Goodwill - Finished pharmaceutical products |  | * | ​ |  | 3,092 | ​ |  | — | ​ |  | 3,092 | ​
Subtotal |  | * | ​ |  | 32,317 | ​ |  | — | ​ |  | 32,317 | ​
As of September 30, 2023 |  | * | ​ | $ | 635,143 | ​ | $ | 15,792 | ​ | $ | 619,351 | ​
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Weighted-Average | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ |
​ |  | Life (Years) |  | Original Cost |  | Amortization |  | Net Book Value |
​ | ​ | (in thousands) |
Definite-lived intangible assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
IMS (UK) international product rights(2) | ​ | 10 | ​ | $ | 8,462 | ​ | $ | 5,430 | ​ | $ | 3,032 | ​
Patents |  | 12 | ​ |  | 486 | ​ | ​ | 362 | ​ |  | 124 | ​
Land-use rights |  | 39 | ​ |  | 2,540 | ​ | ​ | 749 | ​ |  | 1,791 | ​
Subtotal |  | 11 | ​ |  | 11,488 | ​ |  | 6,541 | ​ |  | 4,947 | ​
Indefinite-lived intangible assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Trademark |  | * | ​ |  | 29,225 | ​ |  | — | ​ |  | 29,225 | ​
Goodwill - Finished pharmaceutical products |  | * | ​ |  | 3,126 | ​ |  | — | ​ |  | 3,126 | ​
Subtotal |  | * | ​ |  | 32,351 | ​ |  | — | ​ |  | 32,351 | ​
As of December 31, 2022 |  | * | ​ | $ | 43,839 | ​ | $ | 6,541 | ​ | $ | 37,298 | ​
* Intangible assets with indefinite lives have an indeterminable average life.
(1) | See Note 3.
(2) | In June 2023, the Company recorded an impairment related to its IMS (UK) international product rights in the amount of $2.7 million. The Company recorded the impairment in the cost of revenue line in its condensed consolidated statement of operations for the nine months ended September 30, 2023
​ Goodwill ​ The changes in the carrying amounts of goodwill are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | December 31, |
​ | ​ | 2023 | ​ | 2022 |
​ | ​ | (in thousands) |
Beginning balance |  | $ | 3,126 |  | $ | 3,313 | ​
Currency translation | ​ |  | (34) | ​ |  | (187) | ​
Ending balance | ​ | $ | 3,092 | ​ | $ | 3,126 | ​
​ Amortization ​ As of September 30, 2023, the expected amortization expense for all intangible assets during the next five fiscal years ended December 31 and thereafter is as follows: ​
​ | ​ | ​ | ​ | ​
​ |  | (in thousands) |
2023 | ​ | $ | 6,180 | ​
2024 | ​ |  | 24,718 | ​
2025 | ​ |  | 24,718 | ​
2026 | ​ |  | 24,718 | ​
2027 | ​ |  | 24,718 | ​
Thereafter | ​ |  | 481,982 | ​
Total amortizable intangible assets | ​ |  | 587,034 | ​
Indefinite-lived intangibles | ​ |  | 32,317 | ​
Total intangibles (net of accumulated amortization) | ​ | $ | 619,351 | ​
​ Primatene® Trademark ​ In January 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene MIST®, an over-the-counter bronchodilator product, recorded at the allocated fair value of $29.2 million, which is its carrying value as of September 30, 2023. ​ The trademark was determined to have an indefinite life. In determining its indefinite life, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors. ​ BAQSIMI® Product Rights ​ As discussed in Note 3, in June 2023, the Company acquired the BAQSIMI® product rights. BAQSIMI® is an emergency nasal spray used to treat severe hypoglycemia. The BAQSIMI® product rights intangible asset is amortized over its estimated useful life of 24 years. ​ In determining the BAQSIMI® product rights’ useful life, the Company considered the following: the expected use of the intangible asset; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration